{"id":"W2958564469","doi":"10.1200/jco.2006.24.18_suppl.7503","title":"Phase II study of rituximab + CHOP followed by <sup>90</sup>Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Mantle cell lymphoma; Neutropenia; Vincristine; Febrile neutropenia; Gastroenterology; CHOP; International Prognostic Index; Ibritumomab tiuxetan; Cyclophosphamide; Lymphoma; Radioimmunotherapy; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003425457,0.001533435,0.002109285,0.0004286173,0.0004739955,0.0009362543,0.001087795,0.001159886,0.002797662],"category_scores_gemma":[0.0009759844,0.0007490134,0.001212402,0.0005435692,0.001279285,0.0007848776,0.0004011639,0.00270375,0.0009823907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120174,"about_ca_system_score_gemma":0.002197817,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001764991,"about_ca_topic_score_gemma":0.002892724,"domain_scores_codex":[0.999156,0.0004935872,0.00004101974,0.0001221054,0.00006425541,0.0001231069],"domain_scores_gemma":[0.9989994,0.0001678807,0.0001658187,0.0001052534,0.00005500952,0.0005066693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8154618,0.103677,0.01329911,0.0003876613,0.001201694,0.0002592199,0.0003934054,0.002116849,0.02298636,0.0001497564,0.00161057,0.03845659],"study_design_scores_gemma":[0.4782384,0.5035179,0.01437299,0.00001805661,0.0003244321,0.0001287128,0.00005341559,0.0006840867,0.00121948,0.00007374289,0.001352619,0.00001626643],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952332,0.0007699845,0.000346104,0.0001756968,0.00008362062,0.002150764,0.0004212702,0.00003994266,0.0007793168],"genre_scores_gemma":[0.989996,0.001091225,0.001485125,0.0007540952,0.0002095723,0.003191258,0.001553869,0.00002606614,0.001692712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003425457,"threshold_uncertainty_score":0.01811582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03392994213060223,"score_gpt":0.3841714004314493,"score_spread":0.3502414583008471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}